

PS5], wherein the first nucleotide sequence is selected from the group consisting of SEQ ID NOS:19-30; and

(b) a second nucleotide sequence which is complementary to the first nucleotide sequence.

Please amend claim 7 as follows:

7. (amended)A composition comprising at least one genotyping oligonucleotide for detecting a polymorphism in the β_2 -adrenergic receptor (β_2 AR) gene at a polymorphic site selected from the group consisting of PS2 and PS5, wherein the oligonucleotide is at least 15 nucleotides long.

Please amend claim 8 as follows:

8. (amended)The composition of claim 7, wherein the genotyping oligonucleotide is an allele-specific oligonucleotide that specifically hybridizes to an allele of the β_2 AR gene at a region containing the polymorphic site, wherein the oligonucleotide comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS:3-6.

Please add the following new dependent claims:

30. (new)The isolated polynucleotide of claim 3, wherein the DNA molecule is an expression vector.
31. (new)A recombinant cell comprising the expression vector of claim 30.
32. (new)The composition of claim 7, wherein the genotyping oligonucleotide is selected from the group consisting of an allele-specific oligonucleotide primer and a primer extension oligonucleotide, wherein the allele-specific oligonucleotide primer is selected from the group consisting of SEQ ID NOS:7-14 and the primer extension oligonucleotide is selected from the group consisting of SEQ ID NOS:15-18.

REMARKS

In the telephonic restriction requirement made June 6, 2002, the Patent Office required restriction between the following groups: Group 1, claims 1-8; Group 2, claims 13-20; Group 3, claims 25-27; Group 4, claim 28; and Group 5, claim 29. On June 11, 2002, Applicants provisionally elected Group 1. This response confirms Applicants election of Group 1, claims 1-